Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b extension study of long-term intravenous vedolizumab safety in pediatric ulcerative colitis or Crohn's disease
MOH_2023-05-03_012603Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of vedolizumab in autoimmune colitis and Crohn's disease (3 arms), sponsored by Takeda. Primary endpoint: Long-term safety profile of intravenous vedolizumab. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on MOH_2023-05-03_012603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-03_012603.